Evidence map›Paper›PMID 40492975›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2025

Early-Onset Movement Disorder Syndrome Caused by Biallelic Variants in PDE1B Encoding Phosphodiesterase 1B.

Tomer Poleg, Noam Hadar, Eyal Kristal, Nicola Y Roberts, Vadim Dolgin, Ilana Aminov, Amit Safran, Nadav Agam, Matan Jean, Ofek Freund and 12 more

Abstract read
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Tomer PolegFaculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel.
Noam HadarFaculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel.
Eyal KristalFaculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel.
Nicola Y RobertsLeeds Institute of Medical Research, University of Leeds, Leeds, UK.
Vadim DolginFaculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel.
Ilana AminovFaculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel.
Amit SafranFaculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel.
Nadav AgamFaculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel.
Matan JeanFaculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel.
Ofek FreundFaculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel.
Eamonn G SheridanLeeds Institute of Medical Research, University of Leeds, Leeds, UK.
James A PoulterLeeds Institute of Medical Research, University of Leeds, Leeds, UK.
Michelle L ThompsonHudsonAlpha Institute of Biotechnology, Huntsville, Alabama, USA.
Yusra AlgoosDepartment of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Salma Al-QahtaniMovement Disorders Program, Neuroscience Centre, King Faisal Specialist Hospital and Research Centre (KFSHRC), Riyadh, Saudi Arabia.
Lama AlAbdiDepartment of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Sateesh MaddirevulaDepartment of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Verity HartillLeeds Institute of Medical Research, University of Leeds, Leeds, UK.
Henry HouldenDepartment of Neuromuscular Disease, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0002-2866-7777
Reza MaroofianDepartment of Neuromuscular Disease, UCL Queen Square Institute of Neurology, London, UK.
Amit NahumPediatric Division, Kaplan Medical Center, Rehovot, Israel, Affiliated to the Hebrew University of Jerusalem and Hadassah Medical School, Jerusalem, Israel.
Ohad S BirkFaculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel.ORCID 0000-0003-1430-1296

Funding

Genomic Diagnosis in Children with Developmental DelayUM1HG007301 · NHGRI · HUDSON-ALPHA INSTITUTE FOR BIOTECHNOLOGY · PI COOPER, GREGORY MICHAEL, MYERS, RICHARD M · 2013 to 2016
$7.5M
Integrative interpretation of the organismal consequences of non-coding variationR01CA197139 · NCI · UNIVERSITY OF WASHINGTON · PI COOPER, GREGORY MICHAEL, SHENDURE, JAY ASHOK · 2015 to 2017
$1.9M
Israel Science Foundation 2463/23Medical Research CouncilMSA TrustNational Institute for Health and Care Research - Biomedical Research CentreNational Institute Health Research/Medical Research Council Clinical Academic Research Partnership award MR/V037617/1NCI NIH HHS R01 CA197139NCI NIH HHS R01CA197139NHGRI NIH HHS UM1 HG007301NHGRI NIH HHS UM1HG007301Sir Jules Thorn Charitable Trust JTA/09UK Research and Innovation Future Leaders Fellowship MR/T02044X/1Wellcome Trust
6 · The paper itself

Abstract

backgroundBreakdown of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in basal ganglia cells through hydrolysis of diesteric bonds, primarily by PDE10A and PDE1B, is essential for normal human movement. While biallelic loss-of-function variants in PDE10A are known to cause hyperkinetic movement disorders, the role of PDE1B in human disease has not been characterized.

objectivesWe aimed to define the phenotypic and molecular characteristics of a novel autosomal recessive disorder caused by biallelic PDE1B variants.

methodsClinical phenotyping by senior geneticists and neurologists, followed by whole exome sequencing, segregation analysis (Sanger sequencing), and molecular studies, including mini-gene splicing assays and protein studies in transfected HEK293 cells.

resultsSeven affected individuals from five unrelated pedigrees presented with an apparently autosomal recessive disorder characterized by hypotonia in infancy, progressing to ataxia and dystonia in early childhood, with developmental delay and intellectual disability. Biallelic PDE1B variants were identified in all affected individuals: three truncating (p.Q45*, p.Q86*, p.S298Afs*6) and three splicing variants (c.594 + 2 T>G, c.735 + 5G>A, c.837-1G>C). Functional studies confirmed that the truncating variants caused loss of the catalytic domain, resulting in truncated or absent functional protein. Splicing variants led to exon skipping, frameshifts, and catalytic domain disruption. These findings establish a causative link between biallelic PDE1B variants and the observed clinical phenotype.

conclusionsBiallelic loss-of-function variants in PDE1B underlie a novel early-onset movement disorder resembling the phenotype associated with PDE10A deficiency. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Indexed as

Cyclic Nucleotide Phosphodiesterases, Type 1Movement DisordersAdolescentAdultChildChild, PreschoolDevelopmental DisabilitiesExome SequencingFemaleHEK293 CellsHumansMalePedigreePhenotypeCyclic Nucleotide Phosphodiesterases, Type 1early onsetexome sequencingmovement disorderPDE1Bphosphodiesterase

Identifiers

PMID40492975
PMCPMC12485581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.